cancer_study_identifier: rcc_iatlas_immotion150_2018
type_of_cancer: rcc
pmid: 29867230
name: Renal Cell Carcinoma (IMmotion150 Clinical Trial, Nat Med. 2018) - iAtlas Harmonized
reference_genome: hg38
description: A randomized phase 2 study of atezolizumab (anti-PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib in 263 patients with treatment-naive metastatic renal cell carcinoma. The reprocessing of raw sequencing data is coordinated by <a href="https://cri-iatlas.org/">CRI iAtlas</a>.
citation: McDermott et al. Nat Med 2018